Head of Sales and Business Development Appointed

SkyePharma Appoints Head of Sales and Business Development

LONDON, UK, 7 September, 2011 - SkyePharma PLC (LSE: SKP) today announces the appointment of Dr. Pierre Delavaud as Executive Vice President Sales & Business Development, at the Company's main research and development facilities in Muttenz, Switzerland.

Pierre Delavaud, 46, has more than 17 years of experience in the pharmaceutical industry, with a strong track record in marketing, sales and global business development of which 14 years have been with the Catalent Group (and its preceding companies). Until recently he was Vice President Sales and Business Development Global Pharmaceutical Softgel. Previous roles at Catalent included VP Business Development Europe, VP Sales and Marketing Pharmaceutical Technology Services Europe and General Manager of the Beinheim Softgel plant. Pierre Delavaud has a Ph.D. in Pharmacy from Nantes University.

Axel Müller, Chief Executive Officer of SkyePharma, said:

"We are delighted to welcome Pierre Delavaud to lead our Sales and Business Development activities. Pierre's international industry experience, combined with his impressive track record in marketing, sales and business development, will help SkyePharma to expand its early stage pipeline and attract additional partnership opportunities. He joins SkyePharma at an exciting time, with preparations for the launch of Flutiform™ in Europe, subject to approval, at an advanced stage and a number of interesting products in the development pipeline."

For further information please contact:

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.